Global Premade AAV Particles Market Growth (Status and Outlook) 2025-2031

The global Premade AAV Particles market size is predicted to grow from US$ 206 million in 2025 to US$ 289 million in 2031; it is expected to grow at a CAGR of 5.8% from 2025 to 2031.

The Adeno-Associated Virus (AAV) is a non-enveloped, small single-stranded DNA Parvovirus that commonly infects humans but has no known pathology. Its genome contains two open reading frames, Rep and Cap, which are flanked by two inverted terminal repeats (ITR). In addition to Rep and Cap, AAV requires a helper plasmid containing the adenovirus genes E2a, E4, and VA. These genes mediate the AAV replication.

United States market for Premade AAV Particles is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Premade AAV Particles is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Premade AAV Particles is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Premade AAV Particles players cover Creative Biogene, GeneCopoeia, OriGene Technologies Inc., Amerigo Scientific, Addgene, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Premade AAV Particles Industry Forecast” looks at past sales and reviews total world Premade AAV Particles sales in 2024, providing a comprehensive analysis by region and market sector of projected Premade AAV Particles sales for 2025 through 2031. With Premade AAV Particles sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Premade AAV Particles industry.

This Insight Report provides a comprehensive analysis of the global Premade AAV Particles landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Premade AAV Particles portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Premade AAV Particles market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Premade AAV Particles and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Premade AAV Particles.

This report presents a comprehensive overview, market shares, and growth opportunities of Premade AAV Particles market by product type, application, key players and key regions and countries.

Segmentation by Type:
Natural Serovar
Variants

Segmentation by Application:
In Vitro Experiments
In Vivo Experiments

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Creative Biogene
GeneCopoeia
OriGene Technologies Inc.
Amerigo Scientific
Addgene
BrainVTA
GeneMedi Lab
FenicsBIO
Charles River Laboratories
PackGene Biotech lnc.
Welgen Inc
Revvity

Please note: The report will take approximately 2 business days to prepare and deliver. Show more